Document Detail


Overview of randomized clinical trials in acute heart failure syndromes.
MedLine Citation:
PMID:  16181824     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Acute heart failure syndromes (AHFS) are among the most frequent causes of hospitalizations in the United States and Europe. Despite current therapies, patients with AHFS have high readmission and mortality rates. The randomized, controlled clinical trial is the standard by which contemporary therapies are evaluated, yet this tool of clinical science only recently has been rigorously applied to the development of novel therapies for patients with AHFS. This review briefly discusses some of the challenges presented in designing a clinical trial of therapies for AHFS and to describe some of the recent trials with respect to these issues in established drugs (such as milrinone, dobutamine, nitroglycerin, nitroprusside, and nesiritide) that have been approved by the US Food and Drug Administration (FDA). Recent trials of current investigational agents, such as levosimendan (the Randomized Multicenter Evaluation of Intravenous Levosimendan Efficacy Versus Placebo in the Short-Term Treatment of Decompensated Heart Failure [REVIVE], the Calcium Sensitizer or Inotrope or None in Low-Output Heart Failure [CASINO] study, and the Survival of Patients with Acute Heart Failure in Need of Intravenous Inotropic Support [SURVIVE] trial), tezosentan (the Randomized Intravenous Tezosentan [RITZ] study and the Value of Endothelin Receptor Inhibition with Tezosentan in Acute Heart Failure Studies [VERITAS]), and tolvaptan (the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure [ACTIV-CHF] study), are also discussed.
Authors:
John R Teerlink
Related Documents :
16630984 - Implantable cardioverter-defibrillator therapy in clinical practice.
19804334 - Future potential of echocardiography in heart failure.
12691644 - Nonpharmacologic options for the management of heart failure.
9833144 - Digitalis therapy--relevance of heart rate reduction.
7260964 - Changes in myocardial oxygen consumption 45 minutes after experimental coronary occlusi...
21603454 - Induced hypothermia as a neuroprotectant in post-cardiac arrest.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  The American journal of cardiology     Volume:  96     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  2005 Sep 
Date Detail:
Created Date:  2005-09-26     Completed Date:  2005-10-17     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  59G-67G     Citation Subset:  AIM; IM    
Affiliation:
Section of Cardiology, San Francisco Veterans Affairs Medical Center and School of Medicine, University of California, San Francisco, San Francisco, California 94121-1545, USA. johnt@itsa.ucsf.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Cardiotonic Agents / therapeutic use*
Heart Failure / drug therapy*,  pathology
Humans
Randomized Controlled Trials as Topic
Syndrome
Vasodilator Agents / therapeutic use*
Chemical
Reg. No./Substance:
0/Cardiotonic Agents; 0/Vasodilator Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndrom...
Next Document:  Pharmacology of new agents for acute heart failure syndromes.